Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) — The “Pharma Hub and Patient Access Support Service Market Size, Share & Trends Analysis Report by Service Type, Service Delivery Type and Region with Growth Forecasts, 2025-2033” has been added to ResearchAndMarkets.com’s offering.
The global pharma hub and patient access support service market is on a significant growth trajectory, with a market size estimated at USD 3.24 billion in 2024, projected to reach USD 7.63 billion by 2033, exhibiting a CAGR of 10.0% between 2025 and 2033. This expansion responds to an increasing demand for advanced medicine management across various specialties and rare & orphan diseases, driving the creation of a patient-centric healthcare ecosystem.
Complexities on the payer side, including prior authorizations, specialty drug formularies, and heightened claim denials, are steering manufacturers towards outsourcing patient onboarding processes. This trend enhances verification solutions and copay/cost-assistance management, elevating the role of dedicated hub providers. The surge in high-cost therapies for specialty and rare diseases from 2021 to 2024 has cemented the need for robust pharma hubs and patient access support services.
Noteworthy is the U.S. FDA’s approval of 37 novel drugs in 2022, with approximately 54% targeting rare diseases. The momentum continued in 2023, with 55 new drugs approved, over half dedicated to rare diseases. Costly therapies like Hemgenix, priced at about USD 3.5 million per dose, and Leqembi, with an annual cost of USD 26,500, underscore the financial and administrative challenges confronting patients and highlight the growing investment in digital hub platforms, benefit verification systems, and patient support programs from pharmaceutical companies.
Strategic initiatives are pivotal to market growth. For instance, in November 2023, Docquity expanded its DocquityCare PAP in Thailand, introducing five PAPs and supporting 250 health care professionals and 100 hospitals to enhance oncological care and treat other life-critical conditions.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 100 |
| Forecast Period | 2024 – 2033 |
| Estimated Market Value (USD) in 2024 | $3.24 Billion |
| Forecasted Market Value (USD) by 2033 | $7.63 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
Companies Featured
- Valeris (Formerly PharmaCord)
- Fortrea
- AssistRx
- CareMetx, LLC
- ConnectiveRx.
- Lash Group
- McKesson Corporation
- Engage
- NS Pharma, Inc. (a wholly owned subsidiary of Nippon Shinyaku Co., Ltd.)
- Cardinal Health
- Envoy Health, Inc.
- EVERSANA
- United BioSource LLC
- Mercalis
- Sciensus
Global Pharma Hub and Patient Access Support Service Market Report Segmentation
Service Type Outlook (Revenue, USD Million, 2021-2033)
- Program Enrollment
- Treatment Navigators
- Reimbursement Services/Affordability Services
- Clinical Educator
- Coordination of Specialty Pharmacy/Dispensing
- Others
Service Delivery Type Outlook (Revenue, USD Million, 2021-2033)
- Integrated Services
- Standalone Services
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
For more information about this report visit https://www.researchandmarkets.com/r/e1rwzc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Pharma Hub and Patient Access Support Service Market
